Verastem, Inc.
FSX: 2VSA.F0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Frankfurt Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Daniel W. Paterson
- Employees
- 78
- Headquarters
- Needham, United States
- IPO year
- 2012
- Market cap
- €285.9M
- Website
- https://www.verastem.com
Loading 2VSA…
Loading profile data…Frequently asked questions about 2VSA
What does Verastem, Inc. (2VSA.F) do?
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK....
Where does 2VSA.F trade?
Verastem, Inc. (2VSA.F) trades on the Frankfurt Stock Exchange.
What sector is 2VSA.F in?
Verastem, Inc. (2VSA.F) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Verastem, Inc.?
Daniel W. Paterson is the chief executive officer of Verastem, Inc. (2VSA.F).
Where is Verastem, Inc. headquartered?
Verastem, Inc. is headquartered in United States.
Does 2VSA.F pay a dividend?
Verastem, Inc. (2VSA.F) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2VSA.F go public?
Verastem, Inc. (2VSA.F) completed its initial public offering in 2012.